ROS1 FUSION-POSITIVE LUNG ADENOCARCINOMA

Clinical trials for ROS1 FUSION-POSITIVE LUNG ADENOCARCINOMA explained in plain language.

Never miss a new study

Get alerted when new ROS1 FUSION-POSITIVE LUNG ADENOCARCINOMA trials appear

Sign up with your email to follow new studies for ROS1 FUSION-POSITIVE LUNG ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

Shrinking lung tumors before surgery: targeted drugs show promise for rare cancer type

Disease control Completed

This study looks at whether giving targeted drugs called ROS1 inhibitors before surgery can help people with a rare form of lung cancer. The drugs, entrectinib or crizotinib, are designed to attack cancer cells with a specific genetic change. Researchers will check how much the t…

Matched conditions: ROS1 FUSION-POSITIVE LUNG ADENOCARCINOMA

Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control

Last updated Jul 17, 2026 00:00 UTC

ROS1 FUSION-POSITIVE LUNG ADENOCARCINOMA

Get alerted when new ROS1 FUSION-POSITIVE LUNG ADENOCARCINOMA trials appear

Shrinking lung tumors before surgery: targeted drugs show promise for rare cancer type